Cargando…
Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
BACKGROUND: Ameloblastomas are uncommon locally aggressive tumors of odontogenic epithelium that rarely metastasize. Currently, there is no standard of care for the metastatic forms. Several studies have shown that ameloblastomas frequently have a BRAF mutation. CASE PRESENTATION: We report a case o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657072/ https://www.ncbi.nlm.nih.gov/pubmed/31340860 http://dx.doi.org/10.1186/s13256-019-2140-6 |
_version_ | 1783438737905025024 |
---|---|
author | Broudic-Guibert, Morgane Blay, Jean-Yves Vazquez, Léa Evrard, Alexandre Karanian, Marie Taïeb, Sophie Hoog-Labouret, Natalie Oukhatar, Céline Mahier Ait Boustany-Grenier, Rania Arnaud, Antoine |
author_facet | Broudic-Guibert, Morgane Blay, Jean-Yves Vazquez, Léa Evrard, Alexandre Karanian, Marie Taïeb, Sophie Hoog-Labouret, Natalie Oukhatar, Céline Mahier Ait Boustany-Grenier, Rania Arnaud, Antoine |
author_sort | Broudic-Guibert, Morgane |
collection | PubMed |
description | BACKGROUND: Ameloblastomas are uncommon locally aggressive tumors of odontogenic epithelium that rarely metastasize. Currently, there is no standard of care for the metastatic forms. Several studies have shown that ameloblastomas frequently have a BRAF mutation. CASE PRESENTATION: We report a case of a 33-year-old Caucasian woman with ameloblastoma diagnosed 30 years ago who developed lung metastasis 19 years ago. Systemic oral treatment with vemurafenib, a BRAF inhibitor, was initiated 28 months ago within the AcSé French basket clinical trial of vemurafenib. CONCLUSIONS: The patient has shown a durable clinical, functional, and radiographic partial response with vemurafenib. These observations suggest the possibility of introducing neoadjuvant and/or adjuvant targeted therapy in locally advanced ameloblastoma to improve outcome. BRAF inhibition has proved to be an efficient strategy in patients with a BRAF-mutated ameloblastoma. |
format | Online Article Text |
id | pubmed-6657072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66570722019-07-31 Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report Broudic-Guibert, Morgane Blay, Jean-Yves Vazquez, Léa Evrard, Alexandre Karanian, Marie Taïeb, Sophie Hoog-Labouret, Natalie Oukhatar, Céline Mahier Ait Boustany-Grenier, Rania Arnaud, Antoine J Med Case Rep Case Report BACKGROUND: Ameloblastomas are uncommon locally aggressive tumors of odontogenic epithelium that rarely metastasize. Currently, there is no standard of care for the metastatic forms. Several studies have shown that ameloblastomas frequently have a BRAF mutation. CASE PRESENTATION: We report a case of a 33-year-old Caucasian woman with ameloblastoma diagnosed 30 years ago who developed lung metastasis 19 years ago. Systemic oral treatment with vemurafenib, a BRAF inhibitor, was initiated 28 months ago within the AcSé French basket clinical trial of vemurafenib. CONCLUSIONS: The patient has shown a durable clinical, functional, and radiographic partial response with vemurafenib. These observations suggest the possibility of introducing neoadjuvant and/or adjuvant targeted therapy in locally advanced ameloblastoma to improve outcome. BRAF inhibition has proved to be an efficient strategy in patients with a BRAF-mutated ameloblastoma. BioMed Central 2019-07-25 /pmc/articles/PMC6657072/ /pubmed/31340860 http://dx.doi.org/10.1186/s13256-019-2140-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Broudic-Guibert, Morgane Blay, Jean-Yves Vazquez, Léa Evrard, Alexandre Karanian, Marie Taïeb, Sophie Hoog-Labouret, Natalie Oukhatar, Céline Mahier Ait Boustany-Grenier, Rania Arnaud, Antoine Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report |
title | Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report |
title_full | Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report |
title_fullStr | Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report |
title_full_unstemmed | Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report |
title_short | Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report |
title_sort | persistent response to vemurafenib in metastatic ameloblastoma with braf mutation: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657072/ https://www.ncbi.nlm.nih.gov/pubmed/31340860 http://dx.doi.org/10.1186/s13256-019-2140-6 |
work_keys_str_mv | AT broudicguibertmorgane persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT blayjeanyves persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT vazquezlea persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT evrardalexandre persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT karanianmarie persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT taiebsophie persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT hooglabouretnatalie persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT oukhatarcelinemahierait persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT boustanygrenierrania persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport AT arnaudantoine persistentresponsetovemurafenibinmetastaticameloblastomawithbrafmutationacasereport |